|
業務類別
|
Biotechnology |
|
業務概覽
|
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. |
| 公司地址
| 701 Tillery Street No. 12, No.1010, Austin, TX, USA, 78702 |
| 電話號碼
| +1 240 243-8000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.faeththerapeutics.com |
| 員工數量
| 29 |
| Dr. Brian C. Stephenson, PhD |
Chief Financial Officer |
-- |
15/06/2026 |
| Mr. Josiah Craver |
Senior Vice President, Finance and Principal Accounting Officer |
美元 372.65K |
15/06/2026 |
| Mr. Christopher W Gerry |
General Counsel and and Corporate Secretary |
美元 398.18K |
15/06/2026 |
| Mr. Anand Kiran Parikh |
Chairman of the Board, President and Chief Executive Officer |
-- |
15/06/2026 |
| Dr. Oliver Maddocks, PhD |
Chief Scientific Officer |
-- |
15/06/2026 |
| Dr. Debbie Chirnomas, M.D.,M.P.H. |
Chief Medical Officer |
-- |
15/06/2026 |
|
|
| Mr. Phillip B. Donenberg |
Director |
13/02/2026 |
| Dr. Karen H. Vousden, PhD |
Independent Director |
10/06/2026 |
| Mr. Bob Holmen |
Independent Director |
15/06/2026 |
| Mr. Anand Kiran Parikh |
Chairman of the Board, President and Chief Executive Officer |
15/06/2026 |
| Dr. Stephen M. Hahn |
Independent Director |
16/04/2026 |
| Ms. Saira Ramasastry |
Independent Director |
16/04/2026 |
|
|
|
|
